| Sep 17 |
23andMe independent directors resign due to no proposal from Wojcicki
|
| Sep 17 |
Independent Directors of 23andMe Resign from Board
|
| Sep 15 |
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
|
| Sep 15 |
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
|
| Sep 14 |
23andMe to pay $30M to settle data breach lawsuit
|
| Sep 13 |
23andMe settles data breach lawsuit for $30 million
|
| Sep 12 |
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
|
| Sep 11 |
23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows
|
| Sep 11 |
23andMe CEO Wojcicki says she would consider other takeover proposals
|
| Sep 3 |
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
|
